Unassociated Document

0001144204-09-017991.txt : 20090331 0001144204-09-017991.hdr.sgml : 20090331 20090331171449 ACCESSION NUMBER: 0001144204-09-017991 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20090331 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20090331 DATE AS OF CHANGE: 20090331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOGENOMICS INC CENTRAL INDEX KEY: 0001077183 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] IRS NUMBER: 742897368 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-72097 FILM NUMBER: 09720124 BUSINESS ADDRESS: STREET 1: 1726 MEDICAL BOULEVARD, SUITE 201 STREET 2: SUITE 201 CITY: NAPLES STATE: FL ZIP: 34108 BUSINESS PHONE: 9419231949 MAIL ADDRESS: STREET 1: 1726 MEDICAL BOULEVARD, SUITE 201 STREET 2: SUITE 201 CITY: NAPLES STATE: FL ZIP: 34108 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN COMMUNICATIONS ENTERPRISES INC DATE OF NAME CHANGE: 19990120 8-K 1 v144941_8k.htm Unassociated Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

March 31, 2009

NEOGENOMICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	333-72097	74-2897368
(State or other jurisdiction of	(Commission File Number)	(I.R.S. Employer
incorporation)		Identification No.)

12701 Commonwealth Drive, Suite 9, Fort Myers, Florida (Address of principal executive offices)	33913 (Zip Code)

(239) 768-0600

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02.

Results of Operations and Financial Condition.

The unaudited consolidated balance sheet of NeoGenomics, Inc. (the “Company”) as of December 31, 2008 and December 31, 2007, the unaudited consolidated statements of operations of the Company for the three and twelve months ended December 31, 2008 and December 31, 2007 and the unaudited consolidated statements of cash flows of the Company for the twelve months ended December 31, 2008 and December 31, 2007 are furnished with this Current Report on Form 8-K as Exhibit 99.1.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.

Financial Statements and Exhibits.

(a)

Not applicable

(b)

Not applicable

(c)

Not applicable

(d)

Exhibits.

99.1

The unaudited consolidated balance sheet of the Company as of December 31, 2008 and December 31, 2007, the unaudited consolidated statements of operations of the Company for the three and twelve months ended December 31, 2008 and December 31, 2007 and the unaudited consolidated statements of cash flows of the Company for the twelve months ended December 31, 2008 and December 31, 2007

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOGENOMICS, INC.

By: /s/Jerome J. Dvonch
Jerome J. Dvonch
Principal Accounting Officer

Date: March 31, 2009

-3-

Exhibit Index

Exhibit No.		Description

99.1		The unaudited consolidated balance sheet of the Company as of December 31, 2008 and December 31, 2007, the unaudited consolidated statements of operations of the Company for the three and twelve months ended December 31, 2008 and December 31, 2007 and the unaudited consolidated statements of cash flows of the Company for the twelve months ended December 31, 2008 and December 31, 2007

-4-

EX-99.1 2 v144941_ex99-1.htm Unassociated Document

Exhibit 99.1

NeoGenomics, Inc.

CONSOLIDATED BALANCE SHEET AS OF

December 31, 2008 and December 31, 2007

(unaudited)


ASSETS	December 31, 2008		December 31, 2007

Cash and cash equivalents	$	468,171	$	210,573

Accounts Receivable (net of allowance for doubtful accounts of $358,642 and $414,548, respectively)		2,913,531		3,236,751

Other Current Assets		973,867		704,918

TOTAL CURRENT ASSETS		4,355,569		4,152,242

PROPERTY AND EQUIPMENT (net of accumulated depreciation of $1,602,594 and $862,030, respectively)		2,875,297		2,108,083

OTHER ASSETS		64,509		260,575

TOTAL	$	7,295,375	$	6,520,900

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES	$	4,390,994	$	3,361,705

LONG TERM LIABILITIES		1,403,271		837,081

TOTAL LIABILITIES		5,794,265		4,198,786

STOCKHOLDERS’ EQUITY		1,501,110		2,322,114

TOTAL	$	7,295,375	$	6,520,900

NeoGenomics, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)


	For the Twelve- Months Ended December 31, 2008			For the Twelve- Months Ended December 31, 2007			For the Three- Months Ended December 31, 2008			For the Three- Months Ended December 31, 2007

REVENUE	$	20,015,319		$	11,504,725		$	5,920,360		$	3,795,316

COST OF REVENUE		9,353,852			5,522,775			2,776,302			1,898,914

GROSS PROFIT		10,661,467			5,981,950			3,144,058			1,896,402

OPERATING EXPENSES:
Selling, general and administrative		11,545,456			9,122,922			3,839,172			3,458,869
Total operating expenses		11,545,456			9,122,922			3,839,172			3,458,869

Income (loss) from operations		(883,989	)		(3,140,972	)		(695,114	)		(1,562,467	)

Other income (loss)
Interest income/(expense), net		(298,597	)		(239,200	)		(99,261	)		(33,395	)
Loss on investments		(200,000	)		-			(200,000	)		-
Other Income (loss)		(498,597	)		(239,200	)		(299,261	)		(33,395	)

NET INCOME (LOSS)	$	(1,382,586	)	$	(3,380,172	)	$	(994,375	)	$	(1,595,862	)

NET INCOME (LOSS) PER SHARE - Basic and Diluted	$	(0.04	)	$	(0.11	)	$	(0.03	)	$	(0.05	)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING – Basic and Diluted		31,506,824			29,764,289			31,870,605			31,374,096

NeoGenomics, Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

	For the Twelve-Months Ended December 31, 2008			For the Twelve-Months Ended December 31, 2007

NET CASH USED IN OPERATING ACTIVITIES	$	(138,306	)	$	(2,642,591	)

NET CASH USED IN INVESTING ACTIVITIES		(501,781	)		(716,144	)

NET CASH PROVIDED BY FINANCING ACTIVITIES		897,685			3,443,042

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		257,598			84,307

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		210,573			126,266

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	468,171		$	210,573

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

Interest paid	$	256,323		$	204,670

Income taxes paid	$	-		$	-

SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

Equipment leased under capital lease	$	1,207,863		$	703,145